Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add filters








Year range
1.
Arq. neuropsiquiatr ; Arq. neuropsiquiatr;76(11): 736-742, Nov. 2018. graf
Article in English | LILACS | ID: biblio-973938

ABSTRACT

ABSTRACT Neuropathic pain is a chronic pain condition caused by damage or dysfunction of the central or peripheral nervous system. Electroacupuncture (EA) has an antinociceptive effect on neuropathic pain, which is partially due to inhibiting astrocyte activation in the spinal cord. We found that an intrathecal injection of 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), a selective adenosine A1 receptor antagonist, reversed the antinociceptive effects of EA in a chronic constriction injury-induced neuropathic pain model. The expression of GFAP in L4-L6 spinal cord was significantly upgraded, while DPCPX suppressed the effect of the EA-mediating inhibition of astrocyte activation, as well as wiping out the EA-induced suppression of cytokine content (TNF-α). These results indicated that the adenosine A1 receptor is involved in EA actions during neuropathic pain through suppressing astrocyte activation as well as TNF-α upregulation of EA, giving enlightenment to the mechanisms of acupuncture analgesia and development of therapeutic targets for neuropathic pain.


RESUMO A dor neuropática é uma condição de dor crônica causada por dano ou disfunção do sistema nervoso central ou periférico. A eletroacupuntura (EA) tem um efeito antinociceptivo durante a dor neuropática, que é parcialmente devido à inibição da ativação de astrócitos na medula espinhal. Descobrimos que a injeção intratecal de 8-ciclopentil-1,3-dipropilxantina (DPCPX), um antagonista seletivo do receptor de adenosina A1, reverteu os efeitos antinociceptivos da EA no modelo de dor neuropática induzida por lesão por constrição crônica (CCI). A expressão da GFAP na medula espinal L4-L6 foi significativamente melhorada, enquanto a DPCPX suprimiu o efeito da inibição mediadora da EA na ativação de astrócitos, bem como eliminou a supressão induzida pela EA do conteúdo de citocina (TNF-α). Esses resultados indicam que o receptor de adenosina A1 está envolvido nas ações da EA durante a dor neuropática, suprimindo a ativação astrocitária, bem como o aumento da TNF-α na EA, fornecendo esclarecimentos sobre os mecanismos de analgesia da acupuntura e o desenvolvimento de alvos terapêuticos para dor neuropática.


Subject(s)
Animals , Male , Rats , Spinal Cord/drug effects , Xanthines/pharmacology , Electroacupuncture/methods , Astrocytes/metabolism , Receptor, Adenosine A1/metabolism , Neuralgia/therapy , Sciatic Nerve/injuries , Spinal Cord/metabolism , Xanthines/administration & dosage , Injections, Spinal , Astrocytes/drug effects , Rats, Sprague-Dawley , Receptor, Adenosine A1/administration & dosage , Disease Models, Animal
2.
Arq. neuropsiquiatr ; Arq. neuropsiquiatr;76(4): 252-256, Apr. 2018. graf
Article in English | LILACS | ID: biblio-888375

ABSTRACT

ABSTRACT Obesity is associated with a chronic and low-grade inflammatory response in the hypothalamus, where astrogliosis occurs with the upregulation of the astrocyte structural protein GFAP. As propentofylline (PPF) has inhibitory effects on astrocyte and microglial activation during inflammation, this study aimed to investigate if this xanthine derivative could decrease the astrocyte reaction induced by a hypercaloric diet (HD). Male Wistar rats were divided into four groups: NDS - rats receiving a normocaloric diet (ND) and daily saline solution; NDP - rats receiving ND and daily PPF (12.5 mg/kg/day, intraperitoneal route); HDS - rats receiving HD and saline solution, HDP - rats receiving HD and PPF. On the 21st day, rats were anesthetized, and perfused, and brains were collected for GFAP immunohistochemical study in the hypothalamus. Results showed that HD induced increased weight gain and hypothalamic astrogliosis. Propentofylline decreased the expression of GFAP in the HDP group, although it did not affect the weight gain induced by this diet.


RESUMO A obesidade está associada com uma resposta inflamatória crônica e de baixo grau no hipotálamo, onde ocorre astrogliose com a superexpressão da proteína astrocitária GFAP. Como a propentofilina (PPF) possui efeitos inibitórios sobre a ativação astrocitária e microglial durante a inflamação, este estudo visou a investigar se esta xantina podia diminuir a reação astrocitária induzida pela dieta hipercalórica (HD). Ratos Wistar machos foram divididos em 4 grupos: NDS- ratos recebendo dieta normocalórica (ND) e solução salina diária; NDP- ratos recebendo ND e PPF diária (12.5 mg/kg/dia, via intraperitoneal); HDS- ratos recebendo HD e solução salina, HDP- ratos recebendo HD e PPF. No 21° dia, os ratos foram perfundidos e os encéfalos, coletados para estudo imuno-histoquímico para a GFAP no hipotálamo. Os resultados mostram que a HD induziu aumento do ganho de peso e astrogliose no hipotálamo. A PPF diminuiu a expressão de GFAP no grupo HD, embora não tenha afetado o ganho de peso induzido por esta dieta.


Subject(s)
Animals , Male , Rats , Xanthines/administration & dosage , Diet, High-Fat/adverse effects , Glial Fibrillary Acidic Protein/analysis , Gliosis/etiology , Hypothalamic Diseases/etiology , Rats, Wistar , Gliosis/prevention & control , Hypothalamic Diseases/prevention & control
3.
Arch. endocrinol. metab. (Online) ; 59(1): 47-53, 02/2015. tab, graf
Article in English | LILACS | ID: lil-746451

ABSTRACT

Objective The diabetic state induced by streptozotocin injection is known to impair oligodendroglial remyelination in the rat brainstem following intracisternal injection with the gliotoxic agent ethidium bromide (EB). In such experimental model, propentofylline (PPF) recently showed to improve myelin repair, probably due to its neuroprotective, antiinflammatory and antioxidant effects. The aim of this study was to evaluate the effect of PPF administration in diabetic rats submitted to the EB-demyelinating model. Materials and methods Adult male rats, diabetic or not, received a single injection of 10 microlitres of 0.1% EB solution into the cisterna pontis. For induction of diabetes mellitus the streptozotocin-diabetogenic model was used (50 mg/kg, intraperitoneal route – IP). Some diabetic rats were treated with PPF (12.5 mg/kg/day, IP route) during the experimental period. The animals were anesthetized and perfused from 7 to 31 days after EB injection and brainstem sections were collected for analysis of the lesions by light and transmission electron microscopy. Results Diabetic rats injected with EB showed larger amounts of myelin-derived membranes in the central areas of the lesions and considerable delay in the remyelinating process played by surviving oligodendrocytes and invading Schwann cells after the 15th day. On the other hand, diabetic rats that received PPF presented lesions similar to those of non-diabetic animals, with rapid remyelination at the edges of the lesion site and fast clearance of myelin debris from the central area. Conclusion The administration of PPF apparently reversed the impairment in remyelination induced by the diabetic state. Arch Endocrinol Metab. 2015;59(1):47-53 .


Subject(s)
Animals , Male , Astrocytes/drug effects , Demyelinating Diseases/drug therapy , Diabetes Mellitus, Experimental/drug therapy , Myelin Sheath/physiology , Neuroprotective Agents/pharmacology , Xanthines/pharmacology , Disease Models, Animal , Demyelinating Diseases/pathology , Diabetes Mellitus, Experimental/chemically induced , Ethidium/toxicity , Microscopy, Electron, Transmission , Macrophages/drug effects , Mesencephalon/pathology , Nerve Regeneration/drug effects , Neuroprotective Agents/administration & dosage , Pons/pathology , Rats, Wistar , Streptozocin , Schwann Cells/drug effects , Xanthines/administration & dosage
4.
Rev. bras. pesqui. méd. biol ; Braz. j. med. biol. res;42(1): 105-113, Jan. 2009. graf
Article in English | LILACS | ID: lil-505425

ABSTRACT

Besides other physiological functions, adenosine-5'-triphosphate (ATP) is also a neurotransmitter that acts on purinergic receptors. In spite of the presence of purinergic receptors in forebrain areas involved with fluid-electrolyte balance, the effect of ATP on water intake has not been investigated. Therefore, we studied the effects of intracerebroventricular (icv) injections of ATP (100, 200 and 300 nmol/µL) alone or combined with DPCPX or PPADS (P1 and P2 purinergic antagonists, respectively, 25 nmol/µL) on water intake induced by water deprivation. In addition, the effect of icv ATP was also tested on water intake induced by intragastric load of 12 percent NaCl (2 mL/rat), acute treatment with the diuretic/natriuretic furosemide (20 mg/kg), icv angiotensin II (50 ng/µL) or icv carbachol (a cholinergic agonist, 4 nmol/µL), on sodium depletion-induced 1.8 percent NaCl intake, and on food intake induced by food deprivation. Male Holtzman rats (280-320 g, N = 7-11) had cannulas implanted into the lateral ventricle. Icv ATP (300 nmol/µL) reduced water intake induced by water deprivation (13.1 ± 1.9 vs saline: 19.0 ± 1.4 mL/2 h; P < 0.05), an effect blocked by pre-treatment with PPADS, but not DPCPX. Icv ATP also reduced water intake induced by NaCl intragastric load (5.6 ± 0.9 vs saline: 10.3 ± 1.4 mL/2 h; P < 0.05), acute furosemide treatment (0.5 ± 0.2 vs saline: 2.3 ± 0.6 mL/15 min; P < 0.05), and icv angiotensin II (2.2 ± 0.8 vs saline: 10.4 ± 2.0 mL/2 h; P < 0.05), without changing icv carbachol-induced water intake, sodium depletion-induced 1.8 percent NaCl intake and food deprivation-induced food intake. These data suggest that central ATP, acting on purinergic P2 receptors, reduces water intake induced by intracellular and extracellular dehydration.


Subject(s)
Animals , Male , Rats , Adenosine Triphosphate/administration & dosage , Drinking/drug effects , Pyridoxal Phosphate/analogs & derivatives , Water Deprivation/physiology , Xanthines/administration & dosage , Adenosine Triphosphate/pharmacology , Drinking/physiology , Eating/drug effects , Eating/physiology , Injections, Intraventricular , Pyridoxal Phosphate/administration & dosage , Pyridoxal Phosphate/pharmacology , Rats, Sprague-Dawley , Receptors, Purinergic P1/agonists , Receptors, Purinergic P1/antagonists & inhibitors , /agonists , /antagonists & inhibitors , Xanthines/pharmacology
5.
Medicina (Ribeiräo Preto) ; Medicina (Ribeirao Preto, Online);25(4): 445-51, out.-dez. 1992.
Article in Portuguese | LILACS | ID: lil-127631

ABSTRACT

Pacientes portadores de asma brônquica podem apresentar episódios de exacerbaçöes de sua sintomatologia, näo controlada com o uso de medicaçöes de período intercrítico. Assim, cabe ao médico reconhecer a gravidade de cada uma dessas exacerbaçöes para a instituiçäo de terapêutica adequada. Dentre os parâmetros que indicam gravidade de uma crise de asma brônquica, säo incluídos o pulso paradoxal, as alteraçöes da respiraçäo, fala e nível de consciência, a taquipnéia, a taquicardia, a ausência de sibilância, a cianose e a hipercarbia. Uma vez reconhecida uma crise grave, deve-se tratar o paciente com agonistas adrenérgicos, oxigenaçäo, hidrataçäo, metilxantinas e corticosteróides. O retardo na administraçäo de corticosteróides tem sido considerado como um dos fatores responsáveis pelo êxito letal em pacientes com crises graves de asma brônquica. Nos casos mais graves, refratários à terapêutica acima referida, säo indicados cuidados intensivos, incluindo ventilaçäo mecânica. Após melhora das manifestaçöes agudas o paciente deve ser orientado quanto à terapêutica pós-crise


Subject(s)
Humans , Adrenal Cortex Hormones/therapeutic use , Adrenergic beta-Agonists/therapeutic use , Asthma/drug therapy , Status Asthmaticus/drug therapy , Fluid Therapy , Oxygen Inhalation Therapy , Parasympatholytics/therapeutic use , Xanthines/therapeutic use , Adrenal Cortex Hormones/administration & dosage , Adrenergic beta-Agonists/administration & dosage , Asthma/classification , Status Asthmaticus/classification , Parasympatholytics/administration & dosage , Respiration, Artificial , Xanthines/administration & dosage
SELECTION OF CITATIONS
SEARCH DETAIL